B. Riley Weighs in on Harrow's Q3 Earnings (NASDAQ:HROW)

Key Points

• B. Riley has raised its Q3 2025 earnings per share (EPS) estimate for Harrow from $0.29 to $0.36 and maintains a "Buy" rating with a price target of $70.00.
• Harrow recently reported EPS of $0.24 for its last quarter, exceeding expectations by $0.23, although its revenue fell short of analyst estimates at $63.74 million.
• Institutional investors control 72.76% of Harrow's stock, highlighting significant investor interest in the company following various stake acquisitions.

Harrow, Inc. (NASDAQ:HROW - Free Report) - Analysts at B. Riley increased their Q3 2025 EPS estimates for Harrow in a research report issued to clients and investors on Tuesday, September 23rd. B. Riley analyst M. Mamtani now forecasts that the company will post earnings per share of $0.36 for the quarter, up from their prior estimate of $0.29. B. Riley has a "Buy" rating and a $70.00 price objective on the stock. The consensus estimate for Harrow's current full-year earnings is ($0.53) per share. B. Riley also issued estimates for Harrow's Q4 2025 earnings at $0.63 EPS and FY2026 earnings at $2.88 EPS.

Harrow (NASDAQ:HROW - Get Free Report) last posted its quarterly earnings results on Monday, August 11th. The company reported $0.24 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.01 by $0.23. Harrow had a negative return on equity of 2.18% and a negative net margin of 4.49%.The business had revenue of $63.74 million for the quarter, compared to analyst estimates of $64.23 million. Harrow has set its FY 2025 guidance at EPS.

Other research analysts have also issued research reports about the stock. Cantor Fitzgerald began coverage on shares of Harrow in a research note on Friday, July 11th. They set an "overweight" rating and a $76.00 price objective on the stock. Zacks Research lowered shares of Harrow from a "strong-buy" rating to a "hold" rating in a research note on Friday, September 12th. HC Wainwright lifted their price target on shares of Harrow from $60.00 to $64.00 and gave the stock a "buy" rating in a research report on Wednesday, August 13th. BTIG Research reissued a "buy" rating and set a $63.00 price target on shares of Harrow in a research report on Wednesday. Finally, Craig Hallum lifted their target price on Harrow from $54.00 to $64.00 and gave the stock a "buy" rating in a report on Tuesday. Seven research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $65.33.

Harrow Price Performance

Shares of HROW opened at $47.88 on Thursday. The company has a current ratio of 0.62, a quick ratio of 0.58 and a debt-to-equity ratio of 0.78. Harrow has a 1 year low of $20.85 and a 1 year high of $59.23. The stock has a market cap of $1.77 billion, a P/E ratio of -191.52 and a beta of 0.33. The stock's 50-day moving average price is $38.05 and its two-hundred day moving average price is $31.04.

Institutional Investors Weigh In On Harrow

Several large investors have recently made changes to their positions in HROW. GF Fund Management CO. LTD. acquired a new stake in Harrow in the fourth quarter valued at $25,000. Quarry LP acquired a new stake in Harrow in the first quarter valued at $32,000. Raymond James Financial Inc. acquired a new stake in Harrow in the 2nd quarter valued at about $48,000. Tower Research Capital LLC TRC lifted its stake in Harrow by 345.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 3,373 shares of the company's stock valued at $103,000 after purchasing an additional 2,615 shares during the last quarter. Finally, State of Wyoming acquired a new stake in Harrow in the 1st quarter valued at about $97,000. Institutional investors and hedge funds own 72.76% of the company's stock.

Harrow Company Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.